Zoetis (NYSE:ZTS) Updates FY 2026 Earnings Guidance

Zoetis (NYSE:ZTS) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.150-6.250 for the period, compared to the consensus estimate of 6.870. The company issued revenue guidance of $9.1 billion-$9.3 billion, compared to the consensus revenue estimate of $9.8 billion.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Barclays lowered their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Stifel Nicolaus decreased their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $118.33.

Zoetis Price Performance

ZTS opened at $74.64 on Thursday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company’s 50 day simple moving average is $76.78 and its 200-day simple moving average is $101.29. Zoetis has a one year low of $71.47 and a one year high of $160.48. The stock has a market capitalization of $31.29 billion, a P/E ratio of 12.38, a price-to-earnings-growth ratio of 1.19 and a beta of 0.74.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis will post 6.87 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Institutional Trading of Zoetis

Institutional investors and hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. grew its stake in shares of Zoetis by 3,311.3% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 158,250 shares of the company’s stock worth $19,912,000 after purchasing an additional 153,611 shares during the period. Strive Financial Group LLC bought a new position in Zoetis during the fourth quarter worth about $390,000. Beacon Pointe Advisors LLC boosted its holdings in Zoetis by 3.6% during the fourth quarter. Beacon Pointe Advisors LLC now owns 9,525 shares of the company’s stock worth $1,198,000 after buying an additional 327 shares during the last quarter. First Citizens Bank & Trust Co. grew its position in shares of Zoetis by 34.8% during the 4th quarter. First Citizens Bank & Trust Co. now owns 58,495 shares of the company’s stock worth $7,360,000 after buying an additional 15,115 shares during the period. Finally, EP Wealth Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $35,365,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.